Combining PRMT1 inhibitors with bortezomib shows synergistic effects against multiple myeloma progression.[50] Furthermore, PRMT1 catalyzes critical arginine methylation at the C‐terminus of METTL14, enhancing its ability to bind RNA and catalyze m6A modification of mRNA. Here, PRMT1 is linked to plasma cell myeloma.